Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Fineline Cube Apr 10, 2026
Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026
Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026
Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026
Company

Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts

Fineline Cube Feb 1, 2023

US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high...

Company Deals Drug

Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116

Fineline Cube Feb 1, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...

Company Drug

Ocumension Completes Enrollment for Global Phase III Study of Myopia Treatment OT-101

Fineline Cube Feb 1, 2023

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced the completion of enrollment for a...

Company Deals

R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline

Fineline Cube Feb 1, 2023

Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...

Company Drug

Hengrui’s HER2-Targeted ADC SHR-A1811 Gains NMPA Clearance for Clinical Trial

Fineline Cube Feb 1, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clearance from the National Medical Products...

Company Drug

Hengrui’s Lutetium [177Lu] Oxy-Octreotide Gains Clinical Clearance in China

Fineline Cube Feb 1, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical clearance from the National Medical...

Company Drug

Changchun BCHT Gains NMPA Approval for Herpes Zoster Vaccine

Fineline Cube Feb 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced receiving marketing approval from the...

Company Drug

Jemincare’s Avatrombopag Market Filing Accepted for Review by China’s CDE

Fineline Cube Feb 1, 2023

China-based Jiangxi Jemincare Group has announced that its market filing for avatrombopag maleate (20mg) has...

Company Drug

Ascletis Receives FDA Approval for Phase IIa Trial of ASC10 in RSV Infection

Fineline Cube Feb 1, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving approval from the US FDA to...

Company Deals

Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development

Fineline Cube Feb 1, 2023

South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...

Company Drug

Sirnaomics Accelerates STP705 Development After Positive Skin Cancer Trial Results

Fineline Cube Feb 1, 2023

Sirnaomics Ltd (HKG: 2257) is advancing the clinical development of STP705 following positive results from...

Company Drug

Betta Pharmaceuticals Gains FDA Approval for Clinical Trial of BPI-460372

Fineline Cube Feb 1, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced receiving clinical trial approval from the US FDA...

Company

Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans

Fineline Cube Feb 1, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...

Company Deals

Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme

Fineline Cube Jan 31, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...

Company

Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates

Fineline Cube Jan 31, 2023

US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...

Company Drug

Kelun’s SKB264 Receives Breakthrough Therapy Designation for Lung Cancer

Fineline Cube Jan 31, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody-drug conjugate (ADC) SKB264,...

Company Drug

Hengrui’s Camrelizumab-Apatinib Combo Approved for Liver Cancer in China

Fineline Cube Jan 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Drug

Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer

Fineline Cube Jan 31, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Drug

Zhaoke Ophthalmology’s Cyclosporine A Eye Gel Nears Market Approval in China

Fineline Cube Jan 31, 2023

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...

Company Drug

Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes

Fineline Cube Jan 31, 2023

Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...

Posts pagination

1 … 550 551 552 … 648

Recent updates

  • C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
  • Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
  • Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
  • Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
  • BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.